King Faisal Specialist Hospital & Research Centre (KFSHRC) has successfully concluded its sixth CAR-T Cell Therapy Preceptorship, bringing together leading specialists and regulatory experts to advance knowledge and practice in Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic cancers. The two-day interactive program includes expert-led sessions, facility tours, and collaborative discussions, underscoring the hospital’s ongoing commitment to innovation, research, and enhancing patient outcomes.
Over its five editions, the preceptorship has drawn participants from more than 15 countries, highlighting KFSHRC’s leadership in precision oncology and its commitment to strengthening clinical capabilities across diverse regions. Through this initiative, the hospital continues to foster international collaboration and empower medical professionals with the latest advancements in cancer care.
It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 20th globally in the list of the world’s top 250 Academic Medical Centres for the second consecutive year and has been recognized as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2024 Brand Finance rankings. Additionally, in the same year, it was ranked among the world’s best 250 hospitals and included in the World’s Best Smart Hospitals list for 2025 by Newsweek magazine. For more information, visit www.kfshrc.edu.sa or contact our media team at mediacoverage@kfshrc.edu.sa.